Different signalling pathways associated with the brain endocannabinoid machinery are being investigated as potential therapeutic targets [51], with recent evidence suggests that blocking cannabinoid machinery mediates anti-tumour effects via the inactivation of traditional cannabinoid receptors (CB1 or CB2) [13,14]. Here, CNR2 is linked to neoplasm.